Gastrinomas are the most common symptomatic, malignant PET in patients with or without MEN1 and sufficient numbers of these patients have been entered into our protocols to allow systematic assessment. Studies are now underway, evaluating the natural history of these tumors including the a definition of factors determining prognosis and cause of death. Our studies have identified a cohort of 25% of patients in whom the gastrinomas have aggressive growth and 25% who have multiple endocrine neoplasia type 1 (MEN1). During this year information from our prospective studies was used to write a number of guideline and position papers with the North American Neuroendocrine Tumor Network and the European Neuroendocrine tumor network. In addition, a prospective study of acid secretory changes in patients post gastrinoma resection was completed showing for the first time insights into factors regulating basal secretion in this time period;a collaborative study of the ability to resect pancreatic endocrine tumors(PETs) thought to invade/encase or involve major blood vessels was completed which showed this should not be a contraindication to surgery is is currently widely thought;an epidemiological study on PETs in Japan was completed , which showed a number of important differences from the West, and a number of consensus conferences and position papers on classification/treatment of various disease aspects were published.Currently studies in progress include a study of the need for lymph node resection during surgery for prognostication and a study of the causes of death of MEN1 patients and identification of important prognostic factors.

Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
2011
Total Cost
$330,719
Indirect Cost
City
State
Country
Zip Code
Norton, Jeffrey A; Krampitz, Geoffrey W; Poultsides, George A et al. (2018) Prospective Evaluation of Results of Reoperation in Zollinger-Ellison Syndrome. Ann Surg 267:782-788
Ito, Tetsuhide; Lee, Lingaku; Jensen, Robert T (2018) Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 25:22-35
Capdevila, Jaume; Bodei, Lisa; Davies, Philippa et al. (2018) UNMET MEDICAL NEEDS IN METASTATIC LUNG AND DIGESTIVE NEUROENDOCRINE NEOPLASMS. Neuroendocrinology :
Lee, Lingaku; Ito, Tetsuhide; Jensen, Robert T (2018) Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 18:837-860
Lee, Lingaku; Ito, Tetsuhide; Jensen, Robert T (2018) Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 19:909-928
Norton, Jeffrey A.; Foster, Deshka S.; Blumgart, Leslie H. et al. (2018) Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA Surg 153:e175083
Lee, Lingaku; Ito, Tetsuhide; Igarashi, Hisato et al. (2018) Dose and schedule modification are required for long-term continuation of sunitinib in Japanese patients with advanced pancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 81:163-169
Foster, Deshka S; Jensen, Robert; Norton, Jeffrey A (2018) Management of Liver Neuroendocrine Tumors in 2018. JAMA Oncol :
Miki, Masami; Ito, Tetsuhide; Hijioka, Masayuki et al. (2017) Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors. Jpn J Clin Oncol 47:520-528
Metz, David C; Cadiot, Guillaume; Poitras, Pierre et al. (2017) Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 4:167-185

Showing the most recent 10 out of 58 publications